1. McManis PG, Low PA, Lagerlund TD. Nerve Blood Flow and Microenvironment, in Peripheral Neuropathy (Dyck PJ, Thomas PK, eds.), Elsevier Saunders, Philadelphia, 2005, pp. 667-680.

2. Kihara M, Low PA. Regulation of rat nerve blood flow: role of epineurial alpha-receptors. J Physiol 1990;422:145-152.

3. Kihara M, Low PA. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 1995;132:180-185.

4. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973-1988.

5. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18:1160-1167.

6. Keegan A, Cotter MA, Cameron NE. Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia 1999;42:343-350.

7. Low PA, Zimmerman BR, Dyck PJ. Comparison of distal sympathetic with vagal function in diabetic neuropathy. Muscle Nerve 1986;9:592-596.

8. Mesangeau D, Laude D, Elghozi JL. Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability. Cardiovasc Res 2000;45:889-899.

9. Hashimoto M, Harada T, Ishikawa T, Obata M, Shibutani Y. Investigation on diabetic auto-nomic neuropathy assessed by power spectral analysis of heart rate variability in WBN/Kob rats. J Electrocardiol 2001;34:243-250.

10. McDowell TS, Chapleau MW, Hajduczok G, Abboud FM. Baroreflex dysfunction in diabetes mellitus. I. Selective impairment of parasympathetic control of heart rate. Am J Physiol 1994;266:H235-H243.

11. Patel KP, Zhang PL. Baroreflex function in streptozotocin (STZ) induced diabetic rats. Diabetes Res Clin Pract 1995;27:1-9.

12. Gouty S, Regalia J, Helke CJ. Attenuation of the afferent limb of the baroreceptor reflex in streptozotocin-induced diabetic rats. Auton Neurosci 2001;89:86-95.

13. Gouty S, Regalia J, Cai F, Helke CJ. Alpha-lipoic acid treatment prevents the diabetes-induced attenuation of the afferent limb of the baroreceptor reflex in rats. Auton Neurosci 2003;108:32-44.

14. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999;48:603-608.

15. Togane Y. Evaluation of the cardiac autonomic nervous system in spontaneously non-insulin-dependent diabetic rats by 123I-metaiodobenzylguanidine imaging. Ann Nucl Med 1999;13:19-26.

16. Ralevic V, Belai A, Burnstock G. Effects of streptozotocin-diabetes on sympathetic nerve, endothelial and smooth muscle function in the rat mesenteric arterial bed. Eur J Pharmacol 1995;286:193-199.

17. Low PA, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study. Brain 1975;98:341-356.

18. Webster GJ, Petch EW, Cowen T. Streptozotocin-induced diabetes in rats causes neuronal deficits in tyrosine hydroxylase and 5-hydroxytryptamine specific to mesenteric perivas-cular sympathetic nerves and without loss of nerve fibers. Exp Neurol 1991;113:53-62.

19. Cohen RA, Tesfamariam B, Weisbrod RM, Zitnay KM. Adrenergic denervation in rabbits with diabetes mellitus. Am J Physiol 1990;259:H55-H61.

20. Schmidt RE, Scharp DW. Axonal dystrophy in experimental diabetic autonomic neuropathy. Diabetes 1982;31:761-770.

21. Schmidt RE, Modert CW, Yip HK, Johnson EM Jr. Retrograde axonal transport of intravenously administered 125I-nerve growth factor in rats with streptozotocin-induced diabetes. Diabetes 1983;32:654-663.

22. Schmidt RE, Plurad SB, Sherman WR, Williamson JR, Tilton RG. Effects of aldose reduc-tase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats. Diabetes 1989; 38:569-579.

23. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Zhang W, Sima AA. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol 2004;63:450-460.

24. Tominaga M, Maruyama H, Vasko MR, Baetens D, Orci L, Unger RH. Morphologic and functional changes in sympathetic nerve relationships with pancreatic alpha-cells after destruction of beta-cells in rats. Diabetes 1987;36:365-373.

25. Kniel PC, Junker U, Perrin IV, Bestetti GE, Rossi GL. Varied effects of experimental diabetes on the autonomic nervous system of the rat. Lab Invest 1986;54:523-530.

26. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995;45:773-780.

27. Quick DC, Kennedy WR, Yoon KS. Ultrastructure of the secretory epithelium, nerve fibers, and capillaries in the mouse sweat gland. Anat Rec 1984;208:491-499.

28. Navarro X, Kennedy WR. Changes in sudomotor nerve territories with aging in the mouse. J Auton Nerv Syst 1990;31:101-107.

29. Cardone C, Dyck PJ. A neuropathic deficit, decreased sweating, is prevented and ameliorated by euglycemia in streptozocin diabetes in rats. J Clin Invest 1990;86:248-253.

30. Anderson LC, Garrett JR, Proctor GB. Morphological effects of sympathetic nerve stimulation on rat parotid glands 3-4 weeks after the induction of streptozotocin diabetes. Arch Oral Biol 1990;35:829-838.

31. Anderson LC, Garrett JR, Suleiman AH, Proctor GB, Chan KM, Hartley R. In vivo secretory responses of submandibular glands in streptozotocin-diabetic rats to sympathetic and parasympathetic nerve stimulation. Cell Tissue Res 1993;274:559-566.

32. Sasaki H, Schmelzer JD, Zollman PJ, Low PA. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathol 1997;93:118-128.

33. McManis PG, Schmelzer JD, Zollman PJ, Low PA. Blood flow and autoregulation in somatic and autonomic ganglia. Comparison with sciatic nerve. Brain 1997;120:445-449.

34. Kishi Y, Schmelzer JD, Yao JK, et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999;48:2045-2051.

35. Schmidt RE, Dorsey DA, Roth KA, Parvin CA, Hounsom L, Tomlinson DR. Effect of streptozotocin-induced diabetes on NGF, P75(NTR) and TrkA content of prevertebral and paravertebral rat sympathetic ganglia. Brain Res 2000;867:146-156.

36. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Escandon E. Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. J Neuropathol Exp Neurol 2001;60:263-273.

37. Schmidt RE, Dorsey DA, Beaudet LN, et al. Inhibition of sorbitol dehydrogenase exacerbates autonomic neuropathy in rats with streptozotocin-induced diabetes. J Neuropathol Exp Neurol 2001;60:1153-1169.

38. Schmidt RE. Neuronal preservation in the sympathetic ganglia of rats with chronic streptozotocin-induced diabetes. Brain Res 2001;921:256-259.

39. Fernyhough P, Schmidt RE. Neurofilaments in diabetic neuropathy. Int Rev Neurobiol 2002;50:115-144.

40. Melman A. Pathophysiologic basis of erectile dysfunction. What can we learn from animal models? Int J Impot Res 2001;13:140-142.

41. Melman A, Christ GJ. Integrative erectile biology. The effects of age and disease on gap junctions and ion channels and their potential value to the treatment of erectile dysfunction. Urol Clin North Am 2001;28:217-231.

42. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine 2004;23:167-176.

43. Rehman J, Christ G, Melman A, Fleischmann J. Intracavernous pressure responses to physical and electrical stimulation of the cavernous nerve in rats. Urology 1998;51:640-644.

44. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:843-850.

45. Vernet D, Cai L, Garban H, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995;136:5709-5717.

46. Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J. Nitric oxide and cyclic GMP in the penis. Mol Urol 1999;3:51-59.

47. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000;190:244-254.

48. Garban H, Vernet D, Freedman A, Rajfer J, Gonzalez-Cadavid N. Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol 1995;268:H467-475.

49. Nehra A, Azadzoi KM, Moreland RB, et al. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculo-genic erectile dysfunction. J Urol 1998;159:2229-2236.

50. Nehra A, Goldstein I, Pabby A, et al. Mechanisms of venous leakage: a prospective clinico-pathological correlation of corporeal function and structure. J Urol 1996;156:1320-1329.

51. Christ GJ, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004;287: H1544-H1553.

52. Christ GJ, Rehman J, Day N, et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 1998;275: H600-H608.

53. Melman A, Zhao W, Davies KP, Bakal R, Christ GJ. The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 2003;170:285-290.

54. Magee TR, Ferrini M, Garban HJ, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002;67:20-28.

Dealing With Erectile Dysfunction

Dealing With Erectile Dysfunction

Whether you call it erectile dysfunction, ED, impotence, or any number of slang terms, erection problems are something many men have to face during the course of their lifetimes.

Get My Free Ebook

Post a comment